Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of CA505 vs Ozempic in Type 2 Diabetes
CTR20231841Phase 3Completed
- Sponsor
- Chongqing Chen'an Biopharmaceutical
- Start
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chongqing Chen'an Biopharmaceutical. Primary endpoint: Change in HbA1c from baseline at 32 weeks. Started Jun 2023; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20231841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231841.